ATG-022
01 May 2023
Trial Summary
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
Acronym:
ATG-022
ACTRN/NCT /ethics:
NCT05718895
Scientific title:
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Sponsor / Cooperative group:
Antengene Corporation (Antengene Biologics Limited )
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-02-01 |
| Anticipated End Date | 2026-06-30 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead/Kate Penta |
| Meggan.ORiley@socru.org.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Sarwan Bishnoi |
| Recruitment Status | Recruiting |